RENX LSE Week ended 07 Aug 2026

Weekly Investor Report

Renalytix Plc · Healthcare · Health Information Services

Open interactive chart View report data
Latest close 0.04 GBP
39.6% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 25.8% above the Trend Line and sits at 15.1% of its 52-week range. The latest completed week returned 39.6%, after a 32.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.

Setup score 42 out of 100
Latest Close 0.04 GBP 7 Aug 2026
1W Return 39.6% latest completed week
4W Return 32.1% short-term follow-through
12W Return 105.6% quarterly tape
Trend Breadth 5.8% 3 of 52 weeks active
Volume Ratio 3.0x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 26.36% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 39.6% Latest completed week; four-week move 32.1%. Indicator stack 3/77 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 26.36% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 6 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 25.8% above the Trend Line and sits at 15.1% of its 52-week range. The latest completed week returned 39.6%, after a 32.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 3.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2212-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.22Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 32.1% over four weeks, 105.6% over 12 weeks, and -50.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W39.6%
4W32.1%
12W105.6%
26W-36.2%
52W-50.7%
Active trend streak0 weeks
Active weeks in one year3
Trend breadth5.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.19Latest activity-pressure read.
Pressure change65.7%Four-week change in activity pressure.
Leadership-29.60Latest relative-leadership reading.
RS change39.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 58% Model confidence 46%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength31/100Blend of value, momentum, and quality. Underlying universe rank 70; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality37/100Profitability and accounting quality. Underlying universe rank 64; rank 1 is best.
Momentum37/100Medium-term price momentum. Underlying universe rank 64; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
40.0%
Gross profit retained from each unit of revenue.
Operating margin
-573.3%
Operating profit retained from revenue.
Free-cash-flow margin
-596.7%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
30.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 6 relevant articles.

0 positive · 6 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-76.1%Distance below the 52-week high.
13-week volatility12.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher5 of 2613 weeks finished lower.
Best week+39.6%Week of 7 Aug.
Worst week-28.9%Week of 13 Feb.
Latest week+39.6%Week of 7 Aug.

Shape of recent returns

Strong gains3
Modest gains2
Flat weeks8
Modest losses3
Sharp losses10
Recent vol12.4%13-week weekly-return volatility.
Base vol15.5%52-week weekly-return volatility.
Up/down split10/24Count of positive and negative weeks in the 52-week window.
Average skew18.7% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape32/100

Trend, activity pressure, participation, and risk combine to a 32/100 tape read.

 Indicator analysis25/100

Latest 12-week confirmation: trend 0/12, activity pressure 7/12, relative leadership 0/12.

Activity pressure 0.22; No reversal markers Next-Week ExpectancyNegative 26.36%

Next-week expectancy is negative with a 26.36% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors34/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 6 relevant articles.

Renalytix Plc Revenue Breakdown – LSE:RENX Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20260.04 GBP39.6%0.03 GBP0.16 GBP1.19-29.607.9MOff
31 Jul 20260.03 GBP0.0%0.03 GBP0.16 GBP1.12-50.39767.4KOff
24 Jul 20260.03 GBP-3.6%0.03 GBP0.17 GBP1.07-50.90908.5KOff
17 Jul 20260.03 GBP-1.8%0.03 GBP0.18 GBP0.96-49.456.4MOff
10 Jul 20260.03 GBP21.7%0.03 GBP0.19 GBP0.72-49.0712.2MOff
3 Jul 20260.02 GBP21.1%0.03 GBP0.19 GBP0.39-59.64259.8KOff
26 Jun 20260.02 GBP0.0%0.04 GBP0.20 GBP0.13-66.8135.2KOff
19 Jun 20260.02 GBP0.0%0.04 GBP0.21 GBP-0.16-67.0984.9KOff
12 Jun 20260.02 GBP2.7%0.04 GBP0.21 GBP-0.46-68.14670.6KOff
5 Jun 20260.02 GBP2.8%0.04 GBP0.22 GBP-0.82-69.331.5MOff
29 May 20260.02 GBP0.0%0.04 GBP0.22 GBP-1.12-70.892.2MOff
22 May 20260.02 GBP0.0%0.05 GBP0.23 GBP-1.34-71.73436.2KOff
15 May 20260.02 GBP0.0%0.05 GBP0.23 GBP-1.35-71.65748.8KOff
8 May 20260.02 GBP0.0%0.05 GBP0.24 GBP-1.41-72.41995.5KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context